Increased striatal dopamine production from L-DOPA following selective inhibition of monoamine oxidase B by R(+)-N-propargyl-1-aminoindan (rasagiline) in the monkey

Journal of Neural Transmission, Supplement

Volumn , Issue 52, 1998, Pages 279-285

  Finberg, J P M ^a,b   Wang, J ^a   Bankiewicz, K ^a   Harvey White, J ^a   Kopin, I J ^a   Goldstein, D S ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; DOPAMINE; HOMOVANILLIC ACID; LEVODOPA; RASAGILINE; UNCLASSIFIED DRUG; AMINE OXIDASE (FLAVIN CONTAINING); INDAN DERIVATIVE; ISOENZYME; MONOAMINE OXIDASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CAUDATE NUCLEUS; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOPAMINE METABOLISM; ENZYME INHIBITION; INTRACEREBRAL DRUG ADMINISTRATION; MACACA; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; CAUDATE NUCLEUS; CORPUS STRIATUM; DOPAMINE; HOMOVANILLIC ACID; INDANS; ISOENZYMES; LEVODOPA; MACACA MULATTA; MICRODIALYSIS; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS;

EID: 0031596702     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-7091-6499-0_28     Document Type: Article

References (17)

1. Birkmayer W, Riederer P, Youdim MBH, Linauer W (1975) The potentiation of the antiakinetic effect after L-DOPA treatment by an inhibitor of MAO-B, deprenyl. J Neural Transm 36: 303-326
2. Colzi A, D'Agostini F, Kettler R, Borroni E, Da Prada M (1990) Effect of selective and reversible MAO inhibitors on dopamine outflow in rat striatum; a microdialysis study. J Neural Transm [Suppl] 32: 79-84
3. Di Monte DA, De Lanney LE, Irwin LE, Royland JE, Chan P, Jalowec MW, Langston JW (1996) Monoamine oxidase-dependent metabolism of dopamine in the striatum and substantia nigra of L-DOPA-treated monkeys. Brain Res 738: 53-59
4. Finberg JPM, Tenne M, Youdim MBH (1981) Tyramine antagonistic properties of AGN-1135, an irreversible inhibitor of monoamine oxidase type B, Br J Pharmacol 73: 65-74
5. Finberg JPM, Wang J, Goldstein DS, Kopin IJ, Bankiewicz KS (1995) Influence of selective inhibiton of monoamine oxidase A or B on striatal metabolism of L-DOPA in hemiparkinsonian rats. J Neurochem 65: 1213-1220
6. Kalir A, Sabbagh A, Youdim MBH (1981) Selective acetylenic "suicide" and reversible inhibitors of monoamine oxidase types A and B. Br J Pharmacol 73: 55-64
7. Knoll J (1978) The possible mechanisms of action of (-)-deprenyl in Parkinson's disease. J Neural Transm 43: 177-198
8. Parkinson's Study Group (1993) Effects of tocopherol and deprenyl on the progression of disability in early. Parkinson's disease. N Engl J Med 321: 1364-1371
9. Paterson IA, Davis BA, Durden BA, Juorio AV, Yu PH, Ivy G, Milgram W, Mendonca A, Wu P, Boulton AA (1995) Inhibition of MAO-B by (-)-deprenyl alters dopamine metabolism in the macaque (macaca fascicularis) brain. Neurochem Res 20: 1503-1510
10. Richards JG, Saura J, Luque JM, Cesurs AM, Gottowik J, Malherbe P, Borroni E, Gray J (1997) Monoamine oxidases: from brainmaps to physiology and transgenics to pathophysiology (this volume)
11. Riederer P, Youdim MBH (1986) Monoamine oxidase activity and monoamine metabolism in brains of Parkinson patients treated with 1-deprenyl. J Neurochem 46: 1359-1365
12. Riederer R, Reynolds JP, Youdim MBH (1981) Selectivity of MAO inhibitors in human brain and their clinical consequences. In: Youdim MBH, Paykel ES (eds) Monoamine oxidase inhibitors: the state of the art. Wiley, Chichester, pp 63-76
13. Tipton KF, Houslay MD, Mantle TJ (1976) The nature and locations of the multiple forms of monoamine oxidase. Elsevier, Amsterdam, pp 5-16
14. (Ciba Foundation Symposium 39)
15. Wachtel SR, Abercrombie E (1994) L-3,4-Dihydroxyphenylalanine-induced dopamine release in the striatum of intact and 6-hydroxydopamine-treated rats: differential effects of monoamine oxidase A and B inhibitors. J Neurochem 63: 108-117
16. Wang J, Skirboll S, Aigner TG, Saunders RC, Bankiewicz KS (1990) Methodology of microdialysis of neostriatum in hemiparkinsonian non-human primates. Exp Neurol 110: 181-186
17. Westlund KN, Denney RM, Kochersperger LM, Rose RM, Abell CW (1985) Distinct monoamine oxidase A and B populations in primate brain. Science 230: 181-183